Physician profile
Don O Kikkawa
NPI 1932202371
$349,755.24
in general payments reported to CMS, 2019-2025
11 companies · $196K in 2025
The $196K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $20K · 2021: $11K · 2022: $16K · 2023: $51K · 2024: $40K · 2025: $196K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $157K · Travel and Lodging: $61K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Honoraria: $12K · Food and Beverage: $2,717 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $156,602.36 |
| Travel and Lodging | $60,705.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,448.49 |
| Honoraria | $11,875.00 |
| Food and Beverage | $2,717.11 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $214,997.45 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $113,746.59 | 2019-2023 | Tepezza |
| Argenx US, INC. | $15,788.06 | 2025 | Vyvgart Hytrulo |
| Genentech USA, INC. | $4,638.65 | 2024 | |
| Allergan, INC. | $163.28 | 2020 | |
| Galderma Laboratories, L.P. | $143.48 | 2020 | |
| Bausch & Lomb Americas INC. | $128.76 | 2025 | Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $69.72 | 2019-2021 | |
| Alcon Vision LLC | $31.29 | 2019 | |
| Oyster Point Pharma, INC. | $27.28 | 2024 | Tyrvaya |
| Misonix INC | $20.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Kikkawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.